Long-Term Efficacy and Safety Data on PP Treatments
Experts discuss recent studies of novel treatments for plaque psoriasis (PP) and the importance of long-term data.
Key Takeaways for the Management of Plaque Psoriasis
Experts in dermatology share final thoughts on the treatment of plaque psoriasis and the ever-changing treatment landscape.
Role of Diversity in Plaque Psoriasis Clinical Trials
Benjamin Lockshin, MD, FAAD, highlights diversity in clinical trials as an unmet need in approaching the treatment of plaque psoriasis.
Symptoms and Severity of AD
Experts discuss the symptoms of atopic dermatitis (AD) and how disease severity may impact symptoms.
The Burden of AD on Pediatric and Adult Patients
Shawn Kwatra, MD, and Peter Lio, MD, FAAD, discuss the burden of atopic dermatitis (AD) and how it may affect pediatric or adult patients.
Tapinarof Selectivity and Mechanism of Action for PP Treatment
Tj Chao, MPAS, and Lauren Miller, MPAS, discuss tapinarof as a treatment for plaque psoriasis (PP).
Aryl Hydrocarbon Receptor Treatments for PP
Lauren Miller, MPAS, and Tj Chao, MPAS, discuss new treatments for plaque psoriasis (PP) and their mechanisms of action.
Plaque Psoriasis Treatment Guidelines
Expert dermatologists discuss the treatment guidelines for plaque psoriasis, and how the decision about treatment is ultimately in the hands of the clinician.
Psychological Impact of Plaque Psoriasis
Nicholas Brownstone, MD, and James Q. Del Rosso, DO, comment on the psychological impact of plaque psoriasis on a patient’s quality of life.
Patient Case #3: 32-Year-Old Male With AD
Expert dermatologists review a final case about a 32-year-old male with AD, highlighting systemic therapy as first-line treatment.
Counseling AD Patients on Injection Concerns
Elizabeth Swanson, MD, shares pearls on how to communicate with AD patients who are uncertain about treatment through self-administered injection.
Topical Therapy Options for PP
Experts discuss the landscape of topical drugs for plaque psoriasis (PP) and key factors in treatment options.
PP Treatment Efficacy
Tj Chao, MPAS, and Lauren Miller, MPAS, highlight treatment efficacy considerations for plaque psoriasis (PP).
Patient Case #3: 48-Year-Old Male With Plaque Psoriasis
Experts in dermatology review a patient case of a 48-year-old man with plaque psoriasis who is having trouble with topical therapy.
Patient Case #2: 60-Year-Old Female With Chronic Intertrigo
Dermatology experts discuss a patient case concerning a 60-year-old woman with chronic intertriginous psoriasis who is taking a biologic drug for inflammatory bowel disease.
Guidelines and Recommendations for Therapies in AD
Experts in dermatology review recommendations for systemic therapies and JAK inhibitors in the management of AD and other factors that guide treatment selection.
Patient Case #2: Adolescent Male With AD
Jonathan I Silverberg, MD, PhD, MPH; Elizabeth Swanson, MD; Brad Glick, DO, MPH, FAOCD; and Andrew Blauvelt, MD, MBA, discuss their initial impressions of an adolescent patient with AD, focusing on systemic therapy.
Drug Class Considerations for Patients With PP
Lauren Miller, MPAS, and Tj Chao, MPAS, discuss how patient goals and education can inform next steps of treatment for plaque psoriasis (PP).
PP Treatment Selection: Best Practices
Experts offer insights on treatment selection and patient education for plaque psoriasis (PP).
Patient Case #1: 29-Year-Old Female With Plaque Psoriasis
Dawn L. Sammons, DO, FAOCD, FAAD, and Benjamin Lockshin, MD, FAAD, review a case of a female patient with a family history of plaque psoriasis.
.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Key Takeaways for the Management of Plaque Psoriasis")
